Browsing WoS İndeksli Yayınlar Koleksiyonu by Author "Paksoy, Nail"

Now showing items 1-2 of 2

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Kilickap, Saadettin; Paksoy, Nil; Bilgin, Burak; Sakin, Abdullah; Ozcan, Erkan; Tatli , Ali Murat; Hizal, Mutlu; Paksoy, Nail; Kahraman, Sedat (Springer, 2022)

Introduction: Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage ...
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Hizal, Mutlu; Bilgin, Burak; Paksoy, Nail; Acikgoz, Ozgur; Sezer, Ahmet; Can, Alper (Springer, 2021)

Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after frst-line EGFR-TKI therapy. In ...